Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma

Abstract Objective TQB3602 is a novel orally bioavailable proteasome inhibitor. This study is the first‐in‐human phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TQB3602 in relapsed/refractory multiple myeloma (RRMM). Methods This is a multic...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenjiao Tang, Yan Li, Li Zhang, Xushu Zhong, Qiushi Liang, Yuhuan Zheng, Yuzhang Liu, Yafei Wang, Xunqiang Wang, Yun Zeng, Baijun Fang, Li Zheng, Ting Niu
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Cancer Medicine
Subjects:
antitumor activity
maximum tolerated dose
proteasome inhibitors
relapsed and refractory multiple myeloma
Online Access:https://doi.org/10.1002/cam4.7435
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.7435

Similar Items